The dual SRD5A1 and SRD5A2 inhibitor, dutasteride, and the selective SRD5A2 inhibitor, finasteride, are extensively used in the treatment of benign prostatic hyperplasia, whereby they decrease local generation of DHT. Here, SRD5A2 is linked to benign prostatic hyperplasia.